Sam Schulman, MD, FRCPC(C)


Professor, Division of Hematology and Thromboembolism McMaster University

Associate Professor, Medicine, Karolinska Institute, Stockholm, Sweden

Director, Clinical Thromboembolism Program Hamilton Health Sciences, Hamilton General Hospital, Hamilton, Ontario

Sam Schulman graduated from Karolinska Institute, Stockholm, Sweden in 1977 and became a specialist in Internal Medicine in 1984, with subspecialties in Hematology and in Coagulation in 1985. That year he also received his Dr Med Sc with the thesis: “Studies on the Medical Treatment of Deep Vein Thrombosis”. He has worked within the field of coagulation disorders continuously since 1984, worked as a consultant at the national Hemophilia Center at Tel Hashomer, Israel 1992-1996 and was director of the Hemophilia Treatment Center in Stockholm 1996-2004.

His major research activities have been clinical studies in venous thromboembolism, including several randomized trials and in hemophilia and its complications. He is currently involved in trials with new antithrombotic agents, such as the oral thrombin inhibitors.

He has been a member of the Executive Committee of the World Federation of Hemophilia (2000-2004) and was chairman of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of ISTH 2005-2008. Dr. Schulman is associate professor in Internal Medicine at Karolinska Institute and since September 2004 also professor in Medicine at McMaster University. He is Director of the Thrombosis Service at HHS-General Hospital in Hamilton and Director of the Clinical Thromboembolism Program of McMaster University. He is also President elect for the ISTH XXV Congress in Toronto 2015.

Education and Professional Standing

F.R.C.P.(C) Hematology, 2004
F.R.C.P.(C) Internal Medicine, 2004
Specialist, Hematology (Israel), 1993
Specialist, Coagulation and Bleeding Disorders (Sweden), 1985
Specialist, Hematology (Sweden), 1985
Specialist, Internal Medicine (Sweden), 1984

HHSC, Hamilton General Hospital Site
37 Barton St. E. Hamilton Ontario L8L 2X2


Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H; THRIVE III Investigators.

Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism.

Sam Schulman, M.D., and Per Lindmarker, M.D., for the Duration of Anticoagulation Trial*
N Engl J Med 2000; 342:1953-1958June 29, 2000DOI: 10.1056/NEJM200006293422604.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Schulman S1, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.

Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H.

For additional research publications please visit: https://www.researchgate.net/researcher/2111680802_Sam_Schulman